Drugs / ICX-RHY-013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01564407 | Jan 2011 → Feb 2014 | congenital contractures, reactive cutaneous fibrous lesion | University of Pittsburgh | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICX-RHY-013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01564407 ↗ |
| Modality | Cell therapy | “ICX-RHY-013 is an investigational medicinal product comprised of viable allogeneic human dermal fibroblast (HDFs) cells suspended in HypoThermosol®-FRS.” NCT01564407 ↗ |